OpenAI acquires Orchestra Bio
OpenAI is buying Orchestra Bio to bring AI-driven operations to life sciences research and development. The deal is meant to help biopharma teams speed up drug development and move new treatments forward.
Related stories
Nscale and Anthropic are reportedly in talks for yet another $45B compute deal
Anthropic is reportedly negotiating a $45 billion compute deal with Nscale. It would add to the long series of very large compute agreements Anthropic has signed over the past year.
AI work assistant startup Town reaches unicorn status after raising $108M just weeks after launch
Town, a startup whose AI agents collaborate with other agents to get work done, has raised $108 million at a $1 billion valuation, only weeks after launching. The Series B was led by Forerunner Ventures and Menlo Ventures, with Andreessen Horowitz also taking part.
Nvidia, Dell back $200M round for AI model developer doubleAI
Tel Aviv-based doubleAI has raised $200 million in a Series A co-led by Lightspeed and Bessemer, with Nvidia and Dell among the other investors. According to CTech, the round values the AI model developer at more than $1 billion.
Jim Cramer says don't chase the AI rebound just yet. Here's what needs to happen first
Jim Cramer has cautioned investors against piling back into AI stocks too quickly after the recent rebound, and set out what he wants to see first.
Jim Cramer says the recent AI stock sell-off echoes a crucial lesson from the 1987 market crash
CNBC host Jim Cramer argues that the 1987 stock market crash holds a lesson for investors after the recent sell-off in AI stocks.